New England Journal of Medicine July 27, 2017

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE)

Karim Fizazi et al.

Bottom Line

The addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly improved overall survival and radiographic progression-free survival in men with newly diagnosed, high-risk metastatic castration-sensitive prostate cancer.

Key Findings

1. At a median follow-up of 30.4 months, median overall survival was significantly longer with abiraterone than with placebo (not reached vs. 34.7 months), resulting in a 38% reduction in the risk of death (HR 0.62; 95% CI, 0.51-0.76; P<0.001) [6.1.1].
2. Median radiographic progression-free survival was dramatically prolonged in the abiraterone group compared to the placebo group (33.0 months vs. 14.8 months; HR 0.47; 95% CI, 0.39-0.55; P<0.001).
3. Treatment with abiraterone significantly improved all secondary endpoints, including delaying the time to pain progression, time to initiation of chemotherapy, time to next subsequent prostate cancer therapy, and time to PSA progression (P<0.001 for all comparisons).
4. Adverse events related to mineralocorticoid excess were more frequent in the abiraterone arm, including grade 3 hypertension (approximately 20% vs. 10%) and grade 3 hypokalemia (approximately 10% vs. 1%).

Study Design

Design
Phase 3 RCT
Double-Blind
Sample
1,199
Patients
Duration
30.4 mo
Median
Setting
Multinational (34 countries)
Population Men with newly diagnosed, high-risk, metastatic, castration-sensitive prostate cancer (high-risk defined as ≥2 of: Gleason score ≥8, ≥3 bone lesions, measurable visceral metastasis).
Intervention Abiraterone acetate (1,000 mg once daily) plus prednisone (5 mg once daily) plus concurrent androgen-deprivation therapy (ADT).
Comparator Dual placebos plus concurrent androgen-deprivation therapy (ADT).
Outcome Overall survival and radiographic progression-free survival (coprimary endpoints).

Study Limitations

The trial exclusively enrolled patients with high-risk metastatic disease (requiring at least two of: Gleason score ≥8, ≥3 bone lesions, or visceral metastases), meaning the direct benefit for low-volume or low-risk mCSPC was not evaluated in this specific study.
Early unblinding due to overwhelming efficacy at the interim analysis led to crossover, which inherently confounds long-term overall survival and the impact of subsequent lines of therapy.
The use of abiraterone necessitated co-administration of prednisone and closer monitoring for mineralocorticoid excess and hepatotoxicity compared to ADT alone.

Clinical Significance

The LATITUDE trial, published concurrently with the STAMPEDE abiraterone data, catalyzed a paradigm shift in the management of metastatic hormone-sensitive prostate cancer. It demonstrated that upfront treatment intensification with a next-generation androgen receptor axis-targeted agent (abiraterone) alongside ADT yields profound survival benefits, establishing a new standard of care over the traditional use of ADT alone.

Historical Context

For decades, androgen-deprivation therapy (ADT) alone was the standard frontline treatment for metastatic prostate cancer. In 2015, the CHAARTED and STAMPEDE trials demonstrated that adding docetaxel chemotherapy to ADT improved survival. The 2017 LATITUDE trial built upon this momentum by evaluating whether an alternative approach—maximum androgen blockade using the CYP17 inhibitor abiraterone acetate—could achieve similar or superior outcomes without the toxicities associated with cytotoxic chemotherapy. The overwhelmingly positive results transformed the therapeutic landscape, establishing early AR-axis inhibition as a core pillar of mCSPC management.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

Abiraterone is administered with prednisone in the LATITUDE trial. Based on the mechanism of action of abiraterone, why is the addition of a corticosteroid physiologically necessary?

Key Response

Abiraterone inhibits CYP17A1, blocking both cortisol and androgen synthesis. The resulting drop in cortisol removes negative feedback on ACTH production from the pituitary. High ACTH drives the accumulation of mineralocorticoid precursors upstream of the block, leading to hypertension, hypokalemia, and fluid retention. Co-administering prednisone replaces glucocorticoids, suppresses ACTH, and prevents this mineralocorticoid excess syndrome.

Resident
Resident

The LATITUDE trial evaluated patients with high-risk metastatic castration-sensitive prostate cancer. What were the specific criteria used to define high-risk in this study, and how do you use this in clinical practice to identify patients who need therapy intensification beyond ADT alone?

Key Response

High-risk was defined as having at least two of three factors: Gleason score 8 or higher, presence of 3 or more lesions on a bone scan, and presence of measurable visceral metastasis. Recognizing these precise criteria is crucial for residents to accurately stratify patients and justify the early intensification of ADT with abiraterone to maximize overall survival.

Fellow
Fellow

Both the LATITUDE trial (using abiraterone) and the CHAARTED trial (using docetaxel) demonstrated significant survival benefits when added to ADT for newly diagnosed metastatic prostate cancer. How do the high-risk criteria of LATITUDE overlap with the high-volume criteria of CHAARTED, and what patient-specific factors drive your choice between these two agents?

Key Response

CHAARTED defined high-volume as 4 or more bone metastases (with at least 1 outside the spine/pelvis) or visceral metastases. This heavily overlaps with LATITUDEs high-risk criteria, though LATITUDE includes Gleason score. Since no prospective head-to-head trials show definitive superiority of one over the other, the choice is driven by patient fitness for chemotherapy, comorbidities (e.g., poorly controlled diabetes or heart failure favor docetaxel to avoid steroid/mineralocorticoid effects), financial toxicity, and patient preference.

Attending
Attending

With the shift of abiraterone into the upfront hormone-sensitive setting as proven by LATITUDE, how does this early exposure alter tumor biology, and what are the practice-changing implications for your sequencing strategy when patients eventually progress to castration-resistant prostate cancer?

Key Response

Early use of a potent androgen receptor pathway inhibitor (ARPI) like abiraterone exerts selective pressure that alters tumor biology, often promoting earlier emergence of AR-V7 splice variants or neuroendocrine differentiation. As a result, sequencing a second ARPI (like enzalutamide) in the castration-resistant setting yields very poor response rates. The practice-changing implication is that upon progression after LATITUDE-style upfront therapy, clinicians must rapidly pivot to alternative mechanisms, such as docetaxel/cabazitaxel, PARP inhibitors for HRR mutations, or Lu-177 PSMA radioligand therapy.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

The LATITUDE trial utilized co-primary endpoints of overall survival and radiographic progression-free survival. From a statistical methodology perspective, how does utilizing co-primary endpoints impact the alpha-spending function, and what are the strategic advantages of this design in long-term oncology trials?

Key Response

Using co-primary endpoints requires partitioning the overall type I error rate (alpha) between the two outcomes to rigorously control the family-wise error rate. The strategic advantage in prostate cancer trials is that radiographic progression-free survival provides an earlier, highly sensitive surrogate read-out of efficacy, allowing for faster trial completion and potential crossover, while overall survival remains the gold-standard definitive endpoint that will mature later due to the long natural history of the disease and effective subsequent therapies.

Journal Editor
Journal Editor

As a reviewer evaluating the LATITUDE manuscript, how do you appraise the studys control arm of ADT plus placebos given the timeline of its design, and does the lack of a docetaxel-containing comparator arm threaten the external validity of the results for a contemporary audience?

Key Response

When LATITUDE was designed in 2013, ADT alone was the standard of care. However, by the time of its publication in 2017, the CHAARTED and STAMPEDE trials had already established ADT plus docetaxel as a new standard for high-volume or high-risk disease. A stringent reviewer would flag that comparing abiraterone to ADT alone limits external validity for contemporary practice, as it leaves clinicians without direct prospective data comparing the new intervention against the contemporary active standard of chemotherapy, forcing reliance on indirect network meta-analyses.

Guideline Committee
Guideline Committee

Following the robust overall survival data from LATITUDE and STAMPEDE, how should clinical practice guidelines formally update the standard of care for mCSPC, and what nuances regarding risk stratification must be explicitly addressed in the recommendation algorithms?

Key Response

Guidelines from the NCCN, AUA, and EAU must update their pathways to reflect a Category 1 recommendation for adding abiraterone and prednisone to ADT in patients with mCSPC. The committee must explicitly highlight that while ADT alone is no longer the standard for robust patients, the LATITUDE data strictly applies to the high-risk subgroup. Therefore, algorithms must clearly define high-risk versus low-risk and high-volume versus low-volume states to help clinicians appropriately choose between abiraterone, docetaxel, other ARPIs, or radiation to the primary tumor based on integrated evidence.

Clinical Landscape

Noteworthy Related Trials

2015

CHAARTED Trial

n = 790 · NEJM

Tested

Docetaxel + ADT

Population

Metastatic hormone-sensitive prostate cancer

Comparator

ADT alone

Endpoint

Overall survival

Key result: Adding docetaxel to ADT significantly prolonged overall survival, especially in patients with high-volume metastatic disease.
2017

STAMPEDE Trial (Abiraterone Arm)

n = 1,917 · NEJM

Tested

Abiraterone acetate + prednisolone + ADT

Population

Locally advanced or metastatic prostate cancer starting ADT

Comparator

ADT alone

Endpoint

Overall survival

Key result: Abiraterone plus ADT significantly improved overall survival and failure-free survival compared to ADT alone.
2019

TITAN Trial

n = 1,052 · NEJM

Tested

Apalutamide + ADT

Population

Metastatic castration-sensitive prostate cancer

Comparator

Placebo + ADT

Endpoint

Radiographic progression-free survival and overall survival

Key result: Apalutamide significantly improved both radiographic progression-free survival and overall survival compared to placebo plus ADT.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis